[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368082-105":59,"doc-detail-368082-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prognostic-value-of-pkm2-expression-in-de-novo-metastatic-colorectal-cancer-patients","Prognostic Value of PKM2 Expression in de novo Metastatic Colorectal Cancer Patients","","Metastatic colorectal cancer (CRC) remains a highly lethal disease, and PKM2, an embryonic M2 isoform of pyruvate kinase regulating glycolysis, is linked to tumor growth and poor outcomes. A prospective cohort study evaluated 80 de novo metastatic CRC patients (June 2022–June 2024) using immunohistochemistry to assess PKM2 expression. High PKM2 expression associated with lower ORR and worse PFS/OS after 13 months, and PKM2 IHC emerged as an independent prognostic factor for overall survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prognostic-value-of-pkm2-expression-in-de-novo-metastatic-colorectal-cancer-patients/368082/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prognostic-value-of-pkm2-expression-in-de-novo-metastatic-colorectal-cancer-patients/368082.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was PKM2 expression measured in the study?","Question",{"text":112,"@type":113},"PKM2 expression was evaluated by immunohistochemistry (IHC) in metastatic colorectal cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What relationship did high PKM2 IHC expression show with treatment response?",{"text":117,"@type":113},"High PKM2 IHC expression was associated with a lower overall response rate (ORR), with P = 0.001.",{"name":119,"@type":110,"acceptedAnswer":120},"Did PKM2 IHC expression affect survival outcomes?",{"text":121,"@type":113},"Yes. After a median follow-up of 13 months, high PKM2 IHC expression correlated with lower progression-free survival (PFS) and overall survival (OS), and PKM2 was concluded to be an independent prognostic factor for OS.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368082,1790209485,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","RESEARCH ARTICLE  \n\n| Editorial Proc | ess: Submission:04/21/2025 Acceptance:08/31/2025 Published:09/13/2025 |\n| --- | --- |\n\nPrognostic Value of PKM2 Expression in de novo Metastatic Colorectal Cancer Patients  \nAhmed Refaat1, Nada Mohammad Hussien1 *, Rabab Mohamed Mumdouh Farghaly1, Marwa T. Hussien2, Abeer Ibrahim1  \nAbstract  \nBackground: Metastatic colorectal cancer (CRC) is considered one of the lethal neoplasms globally. The embryonic M2 isoform of pyruvate kinase (PKM2), a crucial enzyme regulating glycolysis, promotes tumor cell proliferation and metastasis, and is correlated with unfavourable outcomes among several cancers, including CRC. Methods: This prospective cohort study included 80 de novo metastatic CRC patients atthe Medical Oncology Department, South Egypt Cancer Institute (SECI), Assiut University, from June 2022 to June 2024. We analyzed the impact of PKM2 expression, evaluated by immunohistochemistry (IHC), in metastatic CRC patients, and response to first-line oxaliplatin-based chemotherapy regimens and survival outcomes in the form of progression-free survival (PFS) and overall survival (OS) . Result: The median age of the studied cases was 47 ys, 42 (52.5%) were male, and 54 (67.5%) were left-sided. Our results revealed a statistically significant association between high PKM2 IHC expression and lower overall response rate (ORR), P = 0.001. After a median follow-up time of 13 months(ms), this translated into a statistically significant association between the high PKM2 IHC expression group and lower PFS and OS (6ms vs 10ms; P = 0.008),(12ms vs. 17ms; P = 0.008), respectively. Conclusion: Our results concluded that PKM2 IHC expression was one of the independent prognostic factors for OS. This supports the consideration of PKM2 as a promising molecular target for therapeutic strategies in CRC management.  \nKeywords: oxaliplatin-response-progression-free survival-overall survival  \nAsian Pac J Cancer Prev, 26 (9), 3485-3493  \nIntroduction  \nCRC is the third most frequently diagnosed cancer worldwide and the second leading cause of cancer-related mortality. In 2022, around 1.9 million people were diagnosed with CRC, and more than 900,000 deaths were related to CRC [1] . In Egypt, CRC ranks as the 7th most common cancer, representing 3.47% of cancers in men and 3% in women [2] .  \nAlthough 70–80% of early colon cancer cases show promise for curative surgical resection, almost half of them will experience metastasis [3] . Approximately 20% of CRC patients presented with distant metastases [4] . Metastasis is the main contributor to mortality from CRC [5]. Although the introduction of new cytotoxic and biologic therapies, anti-epidermal growth factor (EGFR), and anti-vascular endothelial growth factor (VEGF), has significantly improved patient prognosis [6] . oxaliplatin, a chemotherapeutic platinum-based agent, remains a cornerstone in the treatment of metastatic CRC [7] .  \nPKM2 is an isoform of the glycolytic enzyme, pyruvate kinase, which catalyzes the final step of glycolysis, converting the phosphoenolpyruvate to pyruvate, leading  \nto net ATP production, a universal energy carrier in cells, during the glycolytic sequence [8] . Beyond its classical role in glycolysis, PKM2 has been implicated in various cellular processes, including gene transcription and regulation of the cell cycle [9, 10] . PKM2 has also been reported to be associated with tumorigenesis [11] . Furthermore, PKM2 contributes to tumor angiogenesis by activating nuclear factor kappa B (NF-κB) and hypoxiainducible factor 1-alpha (HIF-1α) [12] .  \nPKM2 is widely expressed in various cancer types [13]. Nevertheless, its role in CRC is controversial. While some studies have reported that PKM2 expression was increased in colon cancer cells, they also found that its upregulation was associated with advanced stages [14] . In contrast, some studies have demonstrated that PKM2 may have a minimal role in colon cancer initiation or progression or","cbCailEh3iK1ukVc","https://ap.wps.com/l/cbCailEh3iK1ukVc","pdf",883419,"English","# Abstract\n# Introduction\n# Aim of this study\n# Materials and Methods\n## Study design and patients","[{\"question\":\"How was PKM2 expression measured in the study?\",\"answer\":\"PKM2 expression was evaluated by immunohistochemistry (IHC) in metastatic colorectal cancer patients.\"},{\"question\":\"What relationship did high PKM2 IHC expression show with treatment response?\",\"answer\":\"High PKM2 IHC expression was associated with a lower overall response rate (ORR), with P = 0.001.\"},{\"question\":\"Did PKM2 IHC expression affect survival outcomes?\",\"answer\":\"Yes. After a median follow-up of 13 months, high PKM2 IHC expression correlated with lower progression-free survival (PFS) and overall survival (OS), and PKM2 was concluded to be an independent prognostic factor for OS.\"}]","Prognostic Value of PKM2 Expression in de novo Metastatic Colorectal Cancer Patients | PDF",1790174899,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33ae389a5e2244902b3a861f4fb680cb.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cffacf6f101bc9c8500c18d0caad3da.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb6e8ca435572cb51ba44a62b040c8b3.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f430462aef28f6f104a8599197bfa11e.webp",980,1385]